TMAO plasma levels lower in PD

This study investigated levels of a gut microbiota metabolite called trimethylamine N-oxide (TMAO) in 85 early stage Parkinson’s disease (PD) patients. 20 healthy control subjects were used to compare findings. Results showed that plasma levels of TMAO were lower in early stage PD patients than control subjects. The study concluded that TMAO is implicated in early-stage PD prognosis. Future research should focus on the prophylactic impact of microbial intervention of the gut in PD.

Seok Jong Chung et al. The gut microbiota-derived metabolite trimethylamine N-oxide as a biomarker in early Parkinson’s disease. Nutrition, 2020, 111090, ISSN 0899-9007.

Want to know more?

Pro-Ven Probiotics aim to provide the best support for both you and your health. If you wish to know more about gut health and staying healthy please do not hesitate to call us on 01639 825107 or alternatively, learn more via our blogs or in-depth proven research.

ProVen Probiotics, Unit 2 Christchurch Road, Baglan Industrial Park, Port Talbot, SA12 7DJ. Tel: 01639 825107

Scroll to Top